New CRISPR case to finally settle the score

The latest CRISPR patent case aims to do what the first didn’t: determine who gets rights to the gene editing technology in eukaryotic cells, a category that covers almost all the cell types that matter to drug developers.

The outcome is likely to shake up the IP rights of CRISPR companies, with the stakes highest for the most advanced biotechs whose therapies rely on CRISPR-Cas9, the foundational technology...